Analyst Scoreboard: 6 Ratings For XencorBenzinga • 10 days ago
Latest Ratings for XNCR
DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Feb 2022BMO CapitalInitiates Coverage OnOutperform Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy
View...
Share to Feed
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart...
In trading on Friday, shares of Xencor, Inc (XNCR) crossed below their 200 day moving average of 21.32, changing hands as low as 20.93 per share. Xencor, Inc shares are currently trading...
This indicator may be signaling that XNCR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
This price move could indicate a change in the trend, and may be a buy signal for investors...
This is a signal that XNCR's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
Xencor, Inc. (NASDAQ:XNCR Get Free Report) CEO Bassil I. Dahiyat sold 12,528 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $23.43...
This indicator may be signaling that XNCR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Xencor, Inc. (NASDAQ:XNCR Get Free Report) CEO Bassil I. Dahiyat sold 2,741 shares of the companys stock in a transaction dated Monday, March 11th. The shares were sold at an average...
Xencor (NASDAQ:XNCR Get Free Report) was upgraded by stock analysts at StockNews.com from a sell rating to a hold rating in a note issued to investors on...